You are here: Home » Current Affairs » News » National
Business Standard

ED raids former Ranbaxy promoters Malvinder, Shivinder Singh in PMLA case

The raids were conducted after the filing of a case under the Prevention of Money Laundering Act

Ranbaxy | Malvinder and Shivinder Singh

Press Trust of India  |  New Delhi 

Shivinder Singh Malvinder Singh
Shivinder Singh (left) with Malvinder Singh (right)

The Enforcement Directorate on Thursday raided multiple premises linked to erstwhile Religare promoters, brothers Malvinder Mohan Singh and Shivinder Mohan Singh, and others in connection with a money laundering case, agency officials said.

They said the raids were conducted at seven locations in Delhi including those connected to the Singh brothers, ex-CMD of Religare Enterprises Ltd (REL) Sunil Godhwani, REL executives N K Ghoshal, Hemant Dhingra after an Enforcement Case Information Case (ECIR), the police equivalent of a case, was filed by the agency. The ECIR has been filed under criminal sections of the Prevention of Money Laundering Act (PMLA) after taking cognisance of a Delhi Police Economic Offences Wing (EOW) complaint filed in December last year.

REL's subsidiary Religare Finvest (RFL) had filed the complaint with the EoW, alleging fraud and misappropriation of funds to the tune of Rs 740 crore and had named the Singh brothers and others. On their part, the Singh brothers had blamed Godhwani for the troubles faced by the group.

The EoW FIR had been registered for various offences including cheating, criminal breach of trust, misappropriation, fraud and forgery and criminal conspiracy. The REL was controlled by the warring Singh brothers until February, 2018. Post their exit from the board of REL in February 2018, the boards of REL and RFL have been re-constituted.

The ED is probing alleged misappropriation of over Rs 2,397 crore funds in this case and is probing companies like Arch Finance Ltd and RHC limited, officials said. The relationship between the Singh brothers, also the erstwhile promoters of Fortis and Ranbaxy, turned sour after allegations of fund diversion from the healthcare chain emerged apart from other charges of financial impropriety. It is said to have further aggravated over payment of arbitration award to Daiichi Sankyo.

Shivinder had offered to pay his share of the ?3,500 crore award to the Japanese drug maker in a dispute related to the acquisition of Laboratories.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, August 01 2019. 13:55 IST